size-exclusion chromatography raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-03 and is reviewed periodically as new material appears.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
== Production == Argon is extracted industrially by the fractional distillation of liquid air in a cryogenic air separation unit; a process that separates liquid nitrogen, which boils at 77.3 K, from argon, which boils at 87.3 K, and liquid oxygen, which boils at 90.2 K. About 700,000 tonnes of argon are produced worldwide every year.
UK and international clinical practice guidelines do not recommend metformin as a first-line treatment or do not recommend it at all, except for people with glucose intolerance. The guidelines suggest clomiphene as the first medication option and emphasize lifestyle modification independently from medical treatment. Metformin treatment decreases the risk of developing type 2 diabetes in people with PMOS who exhibited impaired glucose tolerance at baseline. In Poland, metformin is listed as an approved and reimbursed treatment for PMOS.
Nicotine is widely used recreationally through tobacco products, electronic cigarettes, and nicotine pouches, and, as of 2024, 1.2 billion people worldwide use tobacco products. It is highly addictive and hard to discontinue. Nicotine is often used compulsively, and dependence can develop within days. Recreational drug users commonly use nicotine for its mood-altering effects. Recreational nicotine products include chewing tobacco, cigars, cigarettes, e-cigarettes, snuff, pipe tobacco, snus, and nicotine pouches. Alcohol infused with nicotine is called nicotini.
Venous ulcer is defined by the American Venous Forum as "a full-thickness defect of skin, most frequently in the ankle region, that fails to heal spontaneously and is sustained by chronic venous disease, based on venous duplex ultrasound testing." Venous ulcers are wounds that are thought to occur due to improper functioning of venous valves, usually of the legs (hence leg ulcers). They are an important cause of chronic wounds, affecting 1% of the population. Venous ulcers develop mostly along the medial distal leg, and can be painful with negative effects on quality of life. Exercise, together with compression stockings, increases healing. The NICE guideline recommends that everyone with a venous leg ulcer, even if healed, should be referred to a vascular specialist for venous duplex ultrasound and assessment for endovenous surgery.
Ado Jimada Gana Muhammad OON (born 18 January 1967) is a Nigerian medical doctor and public health administrator who serves as Global Programme Director of the D-8 Health and Social Protection Programme. He previously served as the Executive Director/CEO of the Nigeria's National Primary Health Care Development Agency (NPHCDA), the government agency responsible for developing national primary health care (PHC) policy and supporting states and local government areas (LGAs) to implement them. Muhammad was appointed to that position on 1 November 2011, by the administration of President Goodluck Jonathan. Prior to his appointment, Muhammad served as a special assistant to the permanent secretary, in the State House, Abuja. Muhammad succeeded Muhammad Ali Pate who was appointed as the Minister of State for Health in 2011.
Sources: en.wikipedia.org
==== Learning Resources, Inc. v. Trump ==== On August 29, 2025, the US Court of Appeals for the Federal Circuit ruled 7-4 that many of the Trump tariffs were invalid. The Appeals Court had ruled that the International Emergency Economic Powers Act (1977), did not grant the broad powers which the Trump administration was claiming. This decision did not affect some specific tariffs, such as steel or aluminum which were increased under other presidential authority. On February 20, 2026, the Supreme Court decided in Learning Resources, Inc. v. Trump that the IEEPA did not authorise the president to impose tariffs. All tariffs imposed under IEEPA were struck down.
==== E. Nerves of the nose ==== The sensations registered by the human nose derive from the first two branches of cranial nerve V, the trigeminal nerve. The nerve listings indicate the respective innervation (sensory distribution) of the trigeminal nerve branches within the nose, the face, and the upper jaw (maxilla).
At the end of the month, it opened a unit in Seoul (owned by 2F Enterprises) and one in Brunei (owned by a subfranchise of A&W Singapore). As of June 1998, A&W only had two restaurants in Mexico. The Cairo branch opened on August 1, 1998, under local franchise American Egyptian Foreign Investments, with Egypt becoming the seventeenth country outside of the United States to open a location. The first co-branded A&W restaurant, tied with Mexican food chain Amigos, opened in Lincoln in 1997. There were plans to increase the amount of co-branded locations across Nebraska by four in the second half of 1998. The goal of the co-branded restaurant was to allure more customers who did not prefer Mexican food. On March 16, 1999, it announced the opening of a restaurant in Dhaka with franchisee Global Supplies Limited due in September that year, with four more planned. The restaurant in Lodi took part in a world record for the largest root beer float of 2562.5 gallons on June 19, 1999, the eve of the eightieth anniversary of the chain. That same year, the chain attempted to enter the Korean market by finding local partners, aiming to grow in the Korean market in the first half of 2000. The plan was ultimately shelved. A&W merged with Long John Silver's to form Yorkshire Global Restaurants based in Lexington, Kentucky in March 1999. Kevin Bazner was promoted president of the chain in July. In 2000, Yorkshire agreed to test multi-branded locations with Tricon Global Restaurants. A grocery location opened in February that year in Idaho.
At the age of 19 he was assigned to war work in the Operational Research Section (ORS) of RAF Bomber Command, where he developed analytical methods for calculating the ideal density for bomber formations to help the Royal Air Force bomb German targets during the Second World War. After the war, Dyson was readmitted to Trinity College, where he obtained a BA degree in mathematics. From 1946 to 1949 he was a fellow of his college, occupying rooms just below those of the philosopher Ludwig Wittgenstein, who resigned his professorship in 1947. In 1947 Dyson published two papers in number theory. Friends and colleagues described him as shy and self-effacing, with a contrarian streak that his friends found refreshing but intellectual opponents found exasperating. "I have the sense that when consensus is forming like ice hardening on a lake, Dyson will do his best to chip at the ice", Steven Weinberg said of him. His friend the neurologist and author Oliver Sacks said: "A favourite word of Freeman's about doing science and being creative is the word 'subversive'. He feels it's rather important not only to be not orthodox, but to be subversive, and he's done that all his life."
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.